This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TEL AVIV, Israel and WHITE PLAINS, N.Y., April 11, 2013 (GLOBE NEWSWIRE) -- Orgenesis Inc. (OTCBB:ORGS) ("Orgenesis" or the "Company"), a development-stage company with a novel therapeutic technology dedicated to converting a patient's own liver cells into functioning insulin-producing cells as a treatment for diabetes, is pleased to announce the appointment of Jay S. Skyler, M.D., to its Scientific Advisory Board.
Dr. Skyler's career in diabetes spans over four decades, where his research interests have concentrated in clinical aspects of diabetes, particularly improving the care of Type 1 diabetes.
Dr. Skyler is a Professor of Medicine, Pediatrics and Psychology at the University of Miami Miller School of Medicine and Deputy Director for Clinical Research and Academic Programs at the Diabetes Research Institute. He also is an Adjunct Professor of Pediatrics at the Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver.
He is a past President of the American Diabetes Association, the International Diabetes Immunotherapy Group, and the Southern Society for Clinical Investigation, and was a Vice-President of the International Diabetes Federation. He served as a member of the Endocrinology, Diabetes, and Metabolism Subspecialty Examining Board of the American Board of Internal Medicine, as Chairman of the Council of Subspecialty Societies of the American College of Physicians (ACP) and a member of the ACP Board of Regents. A frequent national and international lecturer, Dr. Skyler has been an author, editor and co-editor of numerous books, monographs, chapters and articles. Dr. Skyler was founding Editor-in-Chief of
"I am excited by this opportunity to assist Orgenesis in advancing the development of its very promising new therapy, which, if successful, may finally satisfy the fundamental unmet clinical need of restoring normal insulin secretion in people with diabetes," commented Dr. Skyler.
"We are truly honored to have Dr. Skyler join our Scientific Advisory Board, which is now comprised of three of the top global thought leaders in diabetes," said Orgenesis President & CEO, Sav DiPasquale. "We look forward to working closely with Dr. Skyler to improve the lives of people living with this disease by bringing our transformational technology to market."